Lung Disease Clinical Trials in Houston, Texas
16 recruitingHouston, Texas
Showing 1–16 of 16 trials
Recruiting
Phase 1Phase 2
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.118 enrolled22 locationsNCT07407933
Recruiting
Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
Intraventricular hemorrhageChronic lung disease of prematurityBronchopulmonary Dysplasia+1 more
OHB Neonatology Ltd.338 enrolled72 locationsNCT03253263
Recruiting
Phase 3
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Interstitial Lung DiseasePulmonary HypertensionPulmonary Hypertension Due to Lung Diseases and Hypoxia
United Therapeutics900 enrolled67 locationsNCT06388421
Recruiting
Phase 3
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting
Phase 3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Progressive Pulmonary FibrosisInterstitial Lung Disease
United Therapeutics698 enrolled159 locationsNCT05943535
Recruiting
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Duke University3,000 enrolled44 locationsNCT01915511
Recruiting
Not Applicable
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Pulmonary HypertensionInterstitial Lung Disease (ILD)
Tempus AI900 enrolled25 locationsNCT06911632
Recruiting
Phase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Progressive Pulmonary FibrosisInterstitial Lung DiseasePulmonary Fibrosis+7 more
Avalyn Pharma Inc.375 enrolled152 locationsNCT06329401
Recruiting
Phase 3
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Lung Diseases, Interstitial
GlaxoSmithKline440 enrolled131 locationsNCT06572384
Recruiting
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
Interstitial Lung DiseasePulmonary Hypertension
United Therapeutics300 enrolled42 locationsNCT05776225
Recruiting
American Lung Association (ALA) Lung Health Cohort
Lung Diseases
Johns Hopkins University4,000 enrolled37 locationsNCT04543461
Recruiting
Phase 2
Platform Clinical Study for Conquering Scleroderma
SclerodermaInterstitial Lung Disease Due to Systemic Disease
Scleroderma Research Foundation, Inc.400 enrolled34 locationsNCT06195072
Recruiting
Phase 2Phase 3
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Scleroderma, SystemicSystemic Sclerosis Associated Interstitial Lung Disease
GlaxoSmithKline300 enrolled131 locationsNCT05878717
Recruiting
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
Chronic Lung DiseaseGraft-Versus-Host DiseaseHematopoietic Cell Transplantation
University of Michigan Rogel Cancer Center375 enrolled6 locationsNCT05866302
Recruiting
Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Interstitial Lung Disease
aTyr Pharma, Inc.25 enrolled15 locationsNCT05892614